Drug intelligence / Profile preview

IIT-1

Development stage: Preclinical
Lead developer: Vita Therapeutics
Modality: Cell Therapies

Overview

IIT-1 is a cell therapy drug candidate developed by Vita Therapeutics. It is being investigated primarily for the treatment of facioscapulohumeral muscular dystrophy, a form of muscular dystrophy affecting skeletal muscles. The therapy falls under the broader category of treatments for nervous system diseases, congenital disorders, and skin and musculoskeletal diseases. As of March 2025, IIT-1 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[8].

Beyond the preview

Go deeper on IIT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IIT-1.

Explore the full profile